NYSE:EW

Edwards Lifesciences Stock Forecast, Price & News

$104.05
-0.71 (-0.68 %)
(As of 06/24/2021 02:21 PM ET)
Add
Compare
Today's Range
$103.76
$105.60
50-Day Range
$87.47
$104.76
52-Week Range
$66.45
$105.10
Volume55,189 shs
Average Volume2.63 million shs
Market Capitalization$64.68 billion
P/E Ratio77.07
Dividend YieldN/A
Beta1.09
30 days | 90 days | 365 days | Advanced Chart
Receive EW News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.


Edwards Lifesciences logo

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.65 out of 5 stars

Medical Sector

377th out of 2,105 stocks

Surgical Appliances & Supplies Industry

8th out of 40 stocks

Analyst Opinion: 2.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Edwards Lifesciences (NYSE:EW) Frequently Asked Questions

Is Edwards Lifesciences a buy right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Edwards Lifesciences stock.
View analyst ratings for Edwards Lifesciences
or view top-rated stocks.

What stocks does MarketBeat like better than Edwards Lifesciences?

Wall Street analysts have given Edwards Lifesciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Edwards Lifesciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Edwards Lifesciences' next earnings date?

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Thursday, July 22nd 2021.
View our earnings forecast for Edwards Lifesciences
.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) announced its earnings results on Monday, April, 19th. The medical research company reported $0.54 EPS for the quarter, beating the Zacks' consensus estimate of $0.47 by $0.07. The medical research company had revenue of $1.22 billion for the quarter, compared to analysts' expectations of $1.16 billion. Edwards Lifesciences had a net margin of 19.02% and a trailing twelve-month return on equity of 27.63%. Edwards Lifesciences's revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.50 earnings per share.
View Edwards Lifesciences' earnings history
.

How has Edwards Lifesciences' stock price been impacted by Coronavirus (COVID-19)?

Edwards Lifesciences' stock was trading at $65.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EW shares have increased by 58.3% and is now trading at $104.16.
View which stocks have been most impacted by COVID-19
.

When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?

Edwards Lifesciences's stock split before market open on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly created shares were distributed to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences issued an update on its FY 2021 earnings guidance on Tuesday, May, 4th. The company provided earnings per share guidance of 2.070-2.270 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.130. The company issued revenue guidance of $4.90 billion-$5.30 billion, compared to the consensus revenue estimate of $5.08 billion.

What price target have analysts set for EW?

17 equities research analysts have issued 1 year price targets for Edwards Lifesciences' stock. Their forecasts range from $85.00 to $111.00. On average, they expect Edwards Lifesciences' stock price to reach $100.50 in the next year. This suggests that the stock has a possible downside of 3.5%.
View analysts' price targets for Edwards Lifesciences
or view top-rated stocks among Wall Street analysts.

Who are Edwards Lifesciences' key executives?

Edwards Lifesciences' management team includes the following people:
  • Mr. Michael A. Mussallem, Chairman & CEO (Age 68, Pay $2.09M)
  • Mr. Scott B. Ullem, Corp. VP & CFO (Age 54, Pay $1.06M)
  • Mr. Donald E. Bobo Jr., Corp. VP of Strategy & Corp. Devel. (Age 59, Pay $970.81k)
  • Mr. Larry L. Wood, Corp. VP of Transcatheter Aortic Valve Replacement (Age 55, Pay $1.01M)
  • Mr. Jean-Luc Lemercier, Corp. VP of Europe, Middle East, Africa, Canada & Latin America (Age 64, Pay $1.13M)
  • Dr. Todd J. Brinton, Corp. VP of Advanced Technology & Chief Scientific Officer
  • Mark Wilterding, VP of Investor Relations
  • Mr. Arnold A. Pinkston, Corp. VP & Gen. Counsel (Age 62)
  • Mr. Dirksen J. Lehman, Corp. VP of Public Affairs
  • Ms. Christine Z. McCauley, Corp. VP of HR (Age 56)

What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?

389 employees have rated Edwards Lifesciences CEO Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among Edwards Lifesciences' employees.

Who are some of Edwards Lifesciences' key competitors?

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), The Home Depot (HD), salesforce.com (CRM), The Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (3.73%), Capital International Investors (3.04%), Brown Advisory Inc. (2.26%), Alliancebernstein L.P. (2.10%), Janus Henderson Group PLC (2.09%) and Geode Capital Management LLC (1.59%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link.
View institutional ownership trends for Edwards Lifesciences
.

Which institutional investors are selling Edwards Lifesciences stock?

EW stock was sold by a variety of institutional investors in the last quarter, including Jackson Square Partners LLC, Jennison Associates LLC, Amundi Asset Management US Inc., Nuveen Asset Management LLC, UBS Asset Management Americas Inc., Los Angeles Capital Management LLC, Victory Capital Management Inc., and The PNC Financial Services Group Inc.. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers, and Scott B Ullem.
View insider buying and selling activity for Edwards Lifesciences
or view top insider-selling stocks.

Which institutional investors are buying Edwards Lifesciences stock?

EW stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Winslow Capital Management LLC, Bank of New York Mellon Corp, Ameriprise Financial Inc., D1 Capital Partners L.P., Capital International Investors, Arrowstreet Capital Limited Partnership, and D. E. Shaw & Co. Inc..
View insider buying and selling activity for Edwards Lifesciences
or or view top insider-buying stocks.

How do I buy shares of Edwards Lifesciences?

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $104.16.

How much money does Edwards Lifesciences make?

Edwards Lifesciences has a market capitalization of $64.75 billion and generates $4.39 billion in revenue each year. The medical research company earns $823.40 million in net income (profit) each year or $1.86 on an earnings per share basis.

How many employees does Edwards Lifesciences have?

Edwards Lifesciences employs 14,900 workers across the globe.

Does Edwards Lifesciences have any subsidiaries?

The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.

When was Edwards Lifesciences founded?

Edwards Lifesciences was founded in 1958.

What is Edwards Lifesciences' official website?

The official website for Edwards Lifesciences is www.edwards.com.

Where are Edwards Lifesciences' headquarters?

Edwards Lifesciences is headquartered at ONE EDWARDS WAY, IRVINE CA, 92614.

How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]


This page was last updated on 6/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.